SavedAdd your journal

Journals / Online Türk Sağlık Bilimleri Dergisi / 2026 / Cilt: 8 Sayı: 3

Is Omalizumab Treatment Used During the COVID-19 Pandemic Effective on the Frequency and Severity of COVID-19?

COVID-19 Pandemisi Sırasında Kullanılan Omalizumab Tedavisi COVID-19 Sıklığı ve Şiddeti Üzerine Etkili midir?

Rabia Öztaş Kara(SAKARYA ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, DERMATOLOJİ ANABİLİM DALI)0000-0003-1828-5844
Bahar Sevimli Dikicier(SAKARYA ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, DERMATOLOJİ ANABİLİM DALI)0000-0002-1912-3946
Ahmet Can Yağmur(SAKARYA ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, DERMATOLOJİ ANABİLİM DALI)0000-0003-0073-8980
Ahmet Kara(SAKARYA UNIVERSITY, SCHOOL OF MEDICINE, MEDICINE PR.)0000-0003-3600-5957
Mahizer Yaldız(SAKARYA ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, DERMATOLOJİ ANABİLİM DALI)0000-0003-0502-9024
Pages
369–374
Publication Date
2023-09-06
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The fact that COVID-19 infection was seen less frequent and urticaria activity scores were lower during the infection in the omalizumab group suggests that omalizumab treatment is safe and convenient to use during COVID-19 infection.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The effects of drugs used in chronic spontaneous urticaria (CSU) and similar chronic dermatological diseases in COVID-19 continue to be the subject of many studies.
📊
Key Findings & Data:The present study aimed to reveal the frequency and severity of COVID-19 infection in CSU patients treated with omalizumab and antihistamines.
💡
Conclusion & Impact:Conclusion: The fact that COVID-19 infection was seen less frequent and urticaria activity scores were lower during the infection in the omalizumab group suggests that omalizumab treatment is safe and convenient to use during COVID-19 infection.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Antihistamin · COVID-19 · insidans

Abstract

Objective: The effects of drugs used in chronic spontaneous urticaria (CSU) and similar chronic dermatological diseases in COVID-19 continue to be the subject of many studies. The present study aimed to reveal the frequency and severity of COVID-19 infection in CSU patients treated with omalizumab and antihistamines. Materials and Methods: CSU patients who were followed up and treated with omalizumab or antihistamines were evaluated retrospectively for clinical conditions with CSU and COVID-19 during the pandemic and compared with the control group regarding the incidence and severity of COVID-19 infection. In addition, urticaria disease severity was also compared with pre-pandemic scores for the CSU group. Results: Real-time reverse transcription-polymerase chain reaction test positivity rate for SARS-CoV-2 was detected in 17.4%, 30.1%, and 34.8% of the patients in omalizumab, antihistamine, and control groups, respectively (p= 0.001). The disease activity scores were increased in both antihistamine and omalizumab treated compared to the pre-covid state CSU patients, while the increase was minor in patients using omalizumab. Conclusion: The fact that COVID-19 infection was seen less frequent and urticaria activity scores were lower during the infection in the omalizumab group suggests that omalizumab treatment is safe and convenient to use during COVID-19 infection.

Özet

Amaç: Kronik spontan ürtiker (KSÜ) ve benzeri kronik dermatolojik hastalıklarda kullanılan ilaçların COVID-19'un seyri üzerindeki etkileri halen pek çok araştırma için çalışma konusu olmaya devam etmektedir. Sunulan çalışmada omalizumab ve antihistaminikler ile tedavi edilen KSÜ hastalarında COVID-19 enfeksiyonunun sıklığını ve şiddetini ortaya koymak hedeflenmiştir. Materyal ve Metot: Omalizumab veya antihistaminiklerle izlenen ve tedavi edilen KSÜ hastalarının, pandemi sırasında KSÜ ve COVID-19 ile klinik durumları retrospektif olarak değerlendirildi ve COVID-19 enfeksiyonunun insidansı ve şiddeti açısından kontrol grubu ile karşılaştırıldı. Ayrıca ürtiker hastalığının şiddeti, KSÜ grubu için pandemi öncesi skorlarla karşılaştırıldı. Bulgular: SARS-CoV-2 için gerçek zamanlı ters transkripsiyon-polimeraz zincir reaksiyonu testi pozitiflik oranı omalizumab, antihistaminik ve kontrol gruplarındaki hastaların sırasıyla %17,4, %30,1 ve %34,8'inde tespit edildi (p= 0,001). Hastalık aktivitesi skorları covid öncesi duruma kıyasla hem antihistaminik hem de omalizumab ile tedavi edilen KSÜ hastalarında artarken, omalizumab kullanan hastalarda artış daha düşük oranda saptanmıştır. Sonuç: Omalizumab grubunda COVID-19 enfeksiyonunun daha az görülmesi ve enfeksiyon sırasında ürtiker aktivite skorlarının daha düşük olması, omalizumab tedavisinin COVID-19 enfeksiyonu sırasında kullanımının güvenli ve uygun olduğunu göstermektedir.

🔖

Cite This Article

Kara, R. Ö., Dikicier, B. S., Yağmur, A. C., Kara, A., Yaldız, M. (2023). Is Omalizumab Treatment Used During the COVID-19 Pandemic Effective on the Frequency and Severity of COVID-19?. Online Türk Sağlık Bilimleri Dergisi, Cilt: 8 Sayı: 3, 369–374. https://doi.org/10.26453/otjhs.1282836

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (20)

  1. Coronavirus Resource Center of the John Hopkins University [Internet]. The COVID-19 testing insights initiative; 2021. https://coronavirus.jhu.edu/. Accessed June 23, 2021.
  2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5
  3. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868-887. doi:10.1111/all.12313
  4. Grieco T, Dies L, Sernicola A, et al. Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatment. Immunotherapy. 2020;12(16):1173-1181. doi:10.2217/imt-2020-0088
  5. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67-75. doi:10.1038/jid.2014.306
  6. Acer E, Kaya Erdogan H, Yüksel Çanakçı N, Saracoglu ZN. The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria. Cutan Ocul Toxicol. 2019;38(1):5-8. doi:10.1080/15569527.2018.1495227
  7. Lommatzsch M, Stoll P, Virchow JC. COVID-19 in a patient with severe asthma treated with Omalizumab. Allergy. 2020;75(10):2705-2708. doi:10.1111/all.14456
  8. Vultaggio A, Agache I, Akdis CA, et al. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. Allergy. 2020;75(11):2764-2774. doi:10.1111/all.14407
  9. Salman A, Alper S, Atakan N, et al. Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology. Turkderm-Turk Arch Dermatol Venereology. 2020;54:71-75. doi:10.4274/turkderm.galenos.2020.80000
  10. Hogan Ii RB, Hogan Iii RB, Cannon T, et al. Dual-histamine receptor blockade with cetirizine-famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm Pharmacol Ther. 2020;63:101942. doi:10.1016/j.pupt.2020.101942
  11. Wang T, Hou W, Fu Z. Preventative effect of OMZ-SPT on lipopolysaccharide-induced acute lung injury and inflammation via nuclear factor-kappa B signaling in mice. Biochem Biophys Res Commun. 2017;485(2):284-289. doi:10.1016/j.bbrc.2017.02.090
  12. Living guidance for clinical management of COVID-19; 2021. https://www.who.int/publications/i/item/WHO 2019-nCoV-clinical-2021-2. Accessed Nov 23, 2021.
  13. Criado PR, Criado RFJ, Pincelli TP, Yoshimoto TA, Naufal GGA, Abdalla BMZ. Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab. Int J Dermatol. 2020;59(10):1294-1295. doi:10.1111/ijd.15134
  14. Alizadeh Aghdam M, Knol EF, van den Elzen M, et al. Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria. Clin Exp Allergy. 2020;50(3):364-371. doi:10.1111/cea.13566
  15. Kritas SK, Ronconi G, Caraffa A, Gallenga CE, Ross R, Conti P. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents. 2020;34(1):9-14. doi:10.23812/20-Editorial-Kritas
  16. Kocatürk E, Salman A, Cherrez-Ojeda I, et al. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy. 2021;76(3):816-830. doi:10.1111/all.14687
  17. Branco ACCC, Yoshikawa FSY, Pietrobon AJ, Sato MN. Role of Histamine in Modulating the Immune Response and Inflammation. Mediators Inflamm. 2018;9524075. doi:10.1155/2018/9524075
  18. Gill MA, Liu AH, Calatroni A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 2018;141(5):1735-1743.e9. doi:10.1016/j.jaci.2017.07.035
  19. Lee JS, Shin EC. The type I interferon response in COVID-19: implications for treatment. Nat Rev Immunol. 2020;20(10):585-586. doi:10.1038/s41577-020-00429-3
  20. Bostan E, Zaid F, Karaduman A, et al. The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study. J Cosmet Dermatol. 2021;20(11):3369-3375. doi:10.1111/jocd.14484